![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication June 3, 2008.
Revised July 26, 2008.
Accepted for publication July 28, 2008.
The M1 muscarinic acetylcholine (mACh) receptor is among a growing number of G protein-coupled receptors that are able to activate multiple signaling cascades. AC-42 is an allosteric agonist that can selectively activate the M1 mACh receptor in the absence of an orthosteric ligand. Allosteric agonists have the potential to stabilize unique receptor conformations, which may in turn cause differential activation of signal transduction pathways. In the present study we have investigated the signaling pathways activated by AC-42, its analog 77-LH-28-1 and a range of orthosteric muscarinic agonists (oxotremorine-M (oxo-M), arecoline and pilocarpine) in Chinese hamster ovary cells recombinantly expressing the human M1 mACh receptor. Each agonist was able to activate G
q/11-dependent signaling, as demonstrated by an increase in [35S]-GTP
S binding to G
q/11 proteins and total [3H]-inositol phosphate accumulation assays in intact cells. All three orthosteric agonists caused significant enhancements in [35S]-GTP
S binding to G
i1/2 subunits over basal, however, neither allosteric ligand produced a significant response. In contrast, both orthosteric and allosteric agonists are able to couple to the G
s/cyclic AMP pathway enhancing forskolin-stimulated cyclic AMP accumulation. These data provide support for the concept that allosteric and orthosteric mACh receptor agonists both stabilize receptor conformations associated with G
q/11- and G
s-dependent signaling, however, AC-42 and 77-LH-28-1, unlike oxo-M, arecoline and pilocarpine, do not appear to promote M1 mACh receptor-G
i1/2 coupling, suggesting that allosteric agonists have the potential to activate distinct subsets of downstream effectors.
Key words:
allosteric agonist, functional selectivity, muscarinic receptor, phosphoinositide turnover, receptor-G protein coupling, signal transduction